CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
GSK835726 10mg +3 moredrug
Likely dose
GSK835726 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00972504
NCT00972504Phase 2Completed
CompareCT.gov

A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000µg), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With Seasonal Allergic Rhinitis

GlaxoSmithKline·interventional·Posted Sep 7, 2009·Updated Aug 2, 2017

In Brief

A Phase 2 clinical trial evaluating GSK835726 10mg, GSK1004723 1000mcg, and 2 other interventions for Rhinitis, Allergic, Seasonal. Completed, enrolled 54 participants across 1 site.

Detailed Summary

This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Seasonal
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 7, 2009
Enrollment StartJun 1, 2009
Primary CompletionAug 1, 2009
Study CompletionAug 14, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.8 years ago

Interventions

GSK835726 10mgdrug

GSK835726 10mg tablet

GSK1004723 1000mcgdrug

GSK1004723 1000mcg nasal spray solution

Cetirizine 10mgdrug

Cetirizine 10mg active comparator

placebodrug

placebo to match actives